GRAIL Stock (NASDAQ:GRAL)

Revenue Ownership Financials Chart Transcripts

Previous Close

$14.80

52W Range

$12.33 - $23.36

50D Avg

$13.82

200D Avg

$14.89

Market Cap

$470.41M

Avg Vol (3M)

$749.33K

Beta

1.31

Div Yield

-

GRAL Company Profile

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1,360

IPO Date

Jun 12, 2024

Website

GRAL Performance

GRAL Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$93.11M	$55.55M	$14.61M
Operating Income	$-796.92M	$-742.46M	$-1.27B
Net Income	$-1.47B	$-5.40B	$-1.25B
EBITDA	$-638.22M	$-587.70M	$-1.21B
Basic EPS	$-47.20	$-173.87	$-40.18
Diluted EPS	$-47.20	$-173.87	$-40.18

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 15, 24 | 4:18 AM

Q2 24Aug 13, 24 | 8:44 PM